Document is current

Article History

Accepted: 11 February 2025

First Online: 15 March 2025

Declarations

:

: The authors did not receive support from any organization for the submitted work.

: G.T. has served, over the last 3 years, on advisory boards/seminars funded by Sanofi, MSD, Eli Lilly, Sobi, Celgene, Daichii Sankyo, Novo Nordisk, Gilead, and Amgen on topics not related to the content of this paper. He is also a scientific coordinator of the academic spin-off “INSPIRE srl,” which has received funding from several pharmaceutical companies (Kiowa Kirin, Shonogi, Shire, Novo Nordisk, and Daichii Sankyo) for conducting observational studies and additional consultancy services on topics not related to the content of this paper. In addition, he is currently a consultant for Viatris in a legal case concerning an adverse reaction to sertraline. The other authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: S.D.F., M.C., and A.S. contributed to literature review and data evaluation. The first draft of the manuscript was written by S.D.F. M.C., L.T., and A.S., and F.M.R critically revised and added extra text. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.